A Phase IB/II Study of Surufatinib and Tislelizumab Immunotherapy in People with Advanced Sarcomas

Share

Full Title

An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects with Advanced Solid Tumors

Purpose

The purpose of this study is to assess the safety and effectiveness of combining the investigational drugs surufatinib and tislelizumab to treat people with advanced alveolar soft-part sarcoma (ASPS) or undifferentiated pleomorphic sarcoma (UPS) that has continued to grow after treatment.

Surufatinib blocks the development of new blood vessels that cancer cells need to grow. Tislelizumab takes the brakes off the immune response so immune cells can find and kill cancer cells. Surufatinib is taken orally (by mouth) and tislelizumab is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced ASPS or UPS that has continued to grow despite treatment.
  • Patients should recover from the serious side effects of prior therapies.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Sujana Movva at 646-888-6787.

Protocol

21-406

Phase

I/II

Investigator